Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multicenter, Dose-escalation Study of LY573636-sodium in Combination With 1) Gemcitabine HCl or 2) Docetaxel or 3) Temozolomide or 4) Cisplatin, or 5) Erlotinib in Patients With Advanced Solid Tumors

NCT01284335 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01284335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01284335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multicenter, Dose-escalation Study of LY573636-sodium in Combination With 1) Gemcitabine HCl or 2) Docetaxel or 3) Temozolomide or 4) Cisplatin, or 5) Erlotinib in Patients With Advanced Solid Tumors
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Terminated
Start date
July 31, 2008
Completion date
May 31, 2016
Enrollment
234 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors